|
|
Résultats pour
 brevets
1.
|
COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS
| Numéro d'application |
18685694 |
| Statut |
En instance |
| Date de dépôt |
2022-08-22 |
| Date de la première publication |
2024-12-05 |
| Propriétaire |
River 2 Renal Corp. (USA)
|
| Inventeur(s) |
Magni, Guido
|
Abrégé
The present disclosure relates to a combination therapy comprising co-administration of a relaxin analogue for example, peptide analogues of the B-chain of human relaxin-2 able to activate the RXFP1 receptor and (b) an analogue of vasopressin (also termed arginne vasopressin (AVP), antidiuretic hormone (ADH), and agripressin) able to activate the V1 receptor, for example terlipressin, to an individual in need thereof in the treatment of a renal disorder, such as renal dysfunction in cirrhosis, hepatorenal syndrome type 1 (HRS-AKI) and type 2 (HRS-NAKI), chronic kidney disease and acute kidney injury, and to preserve renal function in peri-operative liver transplantation. This disclosure also relates to compositions comprising relaxin analogues and/or vasopressin analogues for co-administration to an individual in need thereof; preparation of such compositions, and use of such compositions for co-administration to an individual in need thereof, and commercial packages thereto.
Classes IPC ?
- C07K 14/64 - Relaxines
- A61K 38/00 - Préparations médicinales contenant des peptides
- A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
- A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
- C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
|
2.
|
COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS
| Numéro de document |
03229783 |
| Statut |
En instance |
| Date de dépôt |
2022-08-22 |
| Date de disponibilité au public |
2023-03-02 |
| Propriétaire |
RIVER 2 RENAL CORP. (USA)
|
| Inventeur(s) |
Magni, Guido
|
Abrégé
The present disclosure relates to a combination therapy comprising co-administration of a relaxin analogue for example, peptide analogues of the B-chain of human relaxin-2 able to activate the RXFP1 receptor and (b) an analogue of vasopressin (also termed arginine vasopressin (AVP), antidiuretic hormone (ADH), and agripressin) able to activate the V1 receptor, for example terlipressin, to an individual in need thereof in the treatment of a renal disorder, such as renal dysfunction in cirrhosis, hepatorenal syndrome type 1 (HRS-AKI) and type 2 (HRS-NAKI), chronic kidney disease and acute kidney injury, and to preserve renal function in peri-operative liver transplantation. This disclosure also relates to compositions comprising relaxin analogues and/or vasopressin analogues for co-administration to an individual in need thereof; preparation of such compositions, and use of such compositions for co-administration to an individual in need thereof, and commercial packages thereto.
Classes IPC ?
- C07K 14/64 - Relaxines
- C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
- C07K 7/16 - OxytocinesVasopressinesPeptides apparentés
- A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
|
3.
|
COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS
| Numéro d'application |
US2022041095 |
| Numéro de publication |
2023/028008 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2022-08-22 |
| Date de publication |
2023-03-02 |
| Propriétaire |
RIVER 2 RENAL CORP. (USA)
|
| Inventeur(s) |
Magni, Guido
|
Abrégé
The present disclosure relates to a combination therapy comprising co-administration of a relaxin analogue for example, peptide analogues of the B-chain of human relaxin-2 able to activate the RXFP1 receptor and (b) an analogue of vasopressin (also termed arginine vasopressin (AVP), antidiuretic hormone (ADH), and agripressin) able to activate the V1 receptor, for example terlipressin, to an individual in need thereof in the treatment of a renal disorder, such as renal dysfunction in cirrhosis, hepatorenal syndrome type 1 (HRS-AKI) and type 2 (HRS-NAKI), chronic kidney disease and acute kidney injury, and to preserve renal function in peri-operative liver transplantation. This disclosure also relates to compositions comprising relaxin analogues and/or vasopressin analogues for co-administration to an individual in need thereof; preparation of such compositions, and use of such compositions for co-administration to an individual in need thereof, and commercial packages thereto.
Classes IPC ?
- C07K 14/64 - Relaxines
- A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
- A61K 38/095 - Oxytocines Vasopressines Peptides apparentés
- A61K 38/22 - Hormones
- C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
- C07K 7/16 - OxytocinesVasopressinesPeptides apparentés
- A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
|
|